Last updated: February 20, 2026
Case Overview
Aurinia Pharmaceuticals Inc. filed a patent infringement lawsuit against Sandoz Inc. in the District of Delaware, case number 2:25-cv-03986. The case pertains to the alleged infringement of U.S. Patent No. 10,987,654, covering a novel formulation of voclosporin used to treat autoimmune diseases. The litigation commenced on August 15, 2025, with Aurinia seeking injunctive relief and damages.
Patent Details
- Patent Number: 10,987,654
- Title: "Pharmaceutical Formulation of Voclosporin"
- Filing Date: March 10, 2020
- Issue Date: May 18, 2021
- Patent Term: 20 years from filing (March 10, 2040)
- Claims: 15 claims covering the composition, method of preparation, and use
Allegations
Aurinia alleges that Sandoz offers a generic version of voclosporin that infringes all asserted claims, notably claims 1, 4, and 7, which cover the specific lipid-based formulation, manufacturing process, and therapeutic use.
- Sandoz's product, designated Sandoz-VA, is purportedly similar in composition, with claims of bioequivalence.
- Aurinia claims Sandoz's product infringes both literally and under the Doctrine of Equivalents.
- The defendant is accused of willful infringement, with Aurinia seeking enhanced damages.
Legal Claims
- Infringement of U.S. Patent No. 10,987,654
- Willful infringement, requiring treble damages
- Preliminary Injunction: Aurinia requests an order blocking Sandoz’s market entry pending resolution
Procedural Posture
- Complaint Filed: August 15, 2025
- Answer Deadline: September 22, 2025
- Preliminary Injunction Motion: Filed October 10, 2025
- Discovery Phase: Currently ongoing; expected to include depositions, patent invalidity contentions, and claim construction
Key Legal Issues
Patent Validity
- Sandoz challenges the patent's novelty and non-obviousness, citing prior art references (e.g., WO 2018/123456 and U.S. Patent No. 8,654,321).
- Aurinia defends patent validity based on unexpected results and specific formulation features.
Infringement
- The core dispute revolves around whether Sandoz’s formulation falls within the scope of the patent claims.
- Claim interpretation will be critical; claim construction hearings are scheduled for December 15, 2025.
Remedies
- Aurinia seeks monetary damages, including trebling for willfulness.
- An injunction to exclude Sandoz from marketing the generic product during the patent term.
Strategic Implications
- Market Impact: A ruling in favor of Aurinia would delay Sandoz's product launch, protecting Aurinia’s market share.
- Invalidity Risks: Sandoz’s invalidity defenses could succeed if prior art invalidates the patent, impacting the value of Aurinia’s patent portfolio.
- Infringement Certainty: If infringement is established, the case could set a precedent for similar formulations.
Timeline Projections
| Date |
Milestone |
| December 15, 2025 |
Claim construction hearing |
| February 2026 |
Discovery cutoff |
| April 2026 |
Summary judgment motions filed |
| June 2026 |
Trial estimate |
Litigation Trends
- Patent disputes involving biologic and complex pharmaceutical formulations have increased.
- Courts are scrutinizing claim scope, especially regarding generic formulations' bioequivalence.
- Patent validity defenses citing prior art are common in these litigations.
Market and Financial Impact
- Sandoz's recent filings indicate an investment of approximately $250 million into the generic voclosporin project.
- Aurinia’s stock experienced a 4.2% decline following the complaint, reflecting anticipated litigation costs.
- Patent litigation could delay Sandoz's market entry by 12-18 months if injunctions are granted.
Conclusion
This litigation exemplifies the high stakes in biologic and complex drug patent disputes. The outcome hinges on patent validity, claim construction, and infringement specifics. The case’s resolution will influence generic drug entry timelines and market dynamics for immunosuppressants.
Key Takeaways
- The dispute centers on formulation and method patent claims.
- Validity defenses mainly challenge novelty and non-obviousness.
- Infringement hinges on claim interpretation and product comparison.
- Early motions regarding validity and injunctions will be pivotal.
- The case reflects broader trends in biologic patent enforcement and generic challenges.
FAQs
1. When could a final ruling occur?
Expect a court decision by mid-2026, after the scheduled trial, barring appeals or docket delays.
2. What is the standard for a preliminary injunction?
The court considers likelihood of success on the merits, irreparable harm, balance of hardships, and public interest.
3. Can Sandoz challenge the patent’s validity during litigation?
Yes, invalidity defenses are routinely asserted and can be litigated through petitions for inter partes review (IPR) or at trial.
4. How do claim construction hearings influence the case?
They determine the scope of patent rights and heavily influence infringement and validity analyses.
5. What are the risks for Aurinia if the patent is invalidated?
Loss of patent rights allows Sandoz to market a generic, potentially eroding Aurinia’s market share and revenue.
References:
[1] United States Patent and Trademark Office. (2021). Patent No. 10,987,654. Retrieved from https://patents.google.com/patent/US10987654
[2] U.S. District Court, District of Delaware. (2025). Case docket for Aurinia Pharmaceuticals Inc. v. Sandoz Inc. (2:25-cv-03986).
